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The concept of leptin resistance posits that elevated endogenous leptin fails to decrease food intake in
obese animals due to diminished leptin signaling. In this issue, Ottaway et al. (2015) use leptin antagonists
to reveal persistence (or even elevation) of endogenous leptin signaling and physiologic action in diet-
induced obesity.Although common (mis)perceptions hold
that obesity results from poor volitional
behavior, body weight is dictated by bio-
logically encoded processes; the dysre-
gulation of these processes leads to
obesity (Myers et al., 2012). The discovery
of the adipose tissue-derived hormone
leptin and its ability to decrease food
intake and body weight in lean (as well
as leptin-deficient obese) animals not
only identified a crucial mediator of
energy balance, but also suggested the
therapeutic potential of leptin (Zhang
et al., 1994). The findings that obese indi-
viduals exhibit elevated circulating leptin
concentrations (commensurate with their
increased adipose mass) and that exoge-
nous leptin poorly suppresses food intake
and body weight in obesity blunted the
initial enthusiasm for leptin as a therapeu-
tic agent, however. Indeed, these obser-
vations suggested that impaired leptin
action (‘‘leptin resistance’’) might play a
role in the initiation and/or maintenance
of obesity (Myers et al., 2012).
The absence of leptin receptor (LepRb)
mutations in the overwhelming majority of
obese people (and animals) revealed that
obesity does not represent a classical
hormone resistance syndrome (in which
the receptor is mutated or absent), how-
ever (Myers et al., 2012). Indeed, in diet-
induced obesity (DIO; which presumably
mirrors human obesity), obese animals
are genetically identical to their lean con-
trols, but made obese by the provision of
highly palatable fat- and sucrose-laden
food. Nonetheless, the inability of phar-
macologic leptin to stimulate LepRb
signals (such as the phosphorylation of
the LepRb second messenger, STAT3
[pSTAT3]) and promote catabolic re-
sponses in DIO and other obese animals
is consistent with impaired LepRb func-
tion in the obese state. Understandinghow leptin works (and may be impaired)
during obesity will reveal potential mecha-
nisms of leptin resistance; it will also
suggest how altered leptin action might
contribute to the development or mainte-
nance of obesity.
While it is clear that the response to
exogenous leptin is diminished in DIO
and other forms of obesity, the function
of endogenous leptin has generally not
been examined, largely because modu-
lating endogenous leptin is difficult. In
this issue of Cell Metabolism, Ottaway
et al. have cleverly taken advantage of
an engineered leptin analog (LA) that
binds LepRb without promoting receptor
activation; LA competes with native leptin
for LepRb binding, acting as a competi-
tive antagonist. As expected, LA does
not alter food intake or body weight in an-
imals null for leptin, LepRb, or melanocor-
tin action (melanocortin signaling is a
crucial mediator of energy balance that
operates downstream of leptin/LepRb),
but either peripheral or i.c.v. LA increases
feeding and body weight in lean mice.
Importantly, DIO animals also eat more
and gain weight in response to LA. While
DIO animals are slightly less sensitive to
low doses of peripherally administered
LA (consistent with increased leptin that
competes with LA for LepRb occupancy
in DIO animals), the maximal response to
i.p. or i.c.v. LA in DIO animals is the
same as for lean mice. Thus, not only
does endogenous leptin suppress food
intake and body weight gain in DIO as
well as lean animals, it does so to the
same extent in DIO and lean mice.
Similarly, the analysis of cellular leptin
action revealed that LA blocks pSTAT3,
as well as decreasing the hypothalamic
expression of two major leptin target
genes, Pomc and Socs3 (Ottaway et al.,
2015). While Pomc (which encodes mela-Cell Metabolismnocortin peptides that are crucial for lep-
tin action) expression is controlled by
a number of convergent pathways,
Socs3 is directly controlled by LepRb/
STAT3 signaling and represents the best
known readout of cell-autonomous tran-
scriptional control by leptin (Allison et al.,
2015; Bjørbaek et al., 1998). While LA
suppresses Pomc expression similarly
in DIO and lean animals, the inhibition of
pSTAT3 and Socs3 expression by LA is
actually greater in DIO animals than in
lean controls, because (in the absence of
LA) pSTAT3 and Socs3 expression are
increased in DIO mice; the final (sup-
pressed) levels are similar in the two
LA-treated groups (Ottaway et al., 2015).
These data are not only consistent with
the similar physiologic actions of LA
in DIO and lean animals, but also reveal
increased LepRb signaling in DIO
animals. Thus, cellular leptin action is
increased in DIO animals in response to
the elevated circulating leptin concentra-
tions in these animals, and it is difficult
to blame obesity on decreased LepRb
signaling.
Given this response to endogenous
leptin in DIO, how are we to understand
the failure of exogenous leptin to promote
pSTAT3 (as well as decreased feeding
and body weight) in DIO? The answer
may lie partly with Socs3 itself, which
encodes the suppressor of cytokine
signaling-3 (SOCS3, which binds to acti-
vated LepRb to inhibit its activity)
(Figure 1; Bjørbaek et al., 1998; Bjo¨rnholm
et al., 2007). The present data suggest
that while elevated Socs3 may limit the
maximal amplitude of LepRb signaling in
DIO mice, it does not reduce LepRb
signaling below baseline. Indeed, since
Socs3 expression is restricted to LepRb
neurons in the hypothalamus and results
from leptin/ LepRb/ STAT3 signaling21, June 2, 2015 ª2015 Elsevier Inc. 791
Figure 1. Feedback Inhibition and the Response to Endogenous
and Exogenous Leptin
Left: Shown is a schematic of crucial element of LepRb signaling. Leptin binds
to the extracellular domain of LepRb, causing a conformational change that
activates the associated Jak2 tyrosine kinase, which then phosphorylates
the indicated residues on the intracellular domain of LepRb. Phosphorylated
Tyr1138 (pY1138) recruits the latent transcription factor, STAT3, leading to
its phosphorylation (pSTAT3) and transcriptional activation. STAT3 increases
the expression of a variety of genes in LepRb neurons, including Socs3. Socs3
expression directly indicates the strength of the intracellular LepRb/ STAT3
signal. SOCS3 protein mediates feedback inhibition on LepRb, however, by
binding pY985 on LepRb and inhibiting Jak2. Right: A graphical representation
of the strength of overall leptin action (as read out by pSTAT3, Socs3 expres-
sion, or leptin-dependent suppression of food intake and body weight) at
circulating leptin concentrations found in normal (lean) animals, obese (e.g.,
DIO) animals, and in response to pharmacologic leptin. The curve shown in
black is the predicted response in the absence of SOCS3 accumulation
(as well as any other LepRb-inhibiting parameters in obese, hyperleptinemic
animals). The dashed blue curve demonstrates the response to leptin in the
presence of SOCS3 and other inhibitors of LepRb action in DIO mice. The
brackets show: (A) the predicted and observed increase in leptin action in
DIO compared to lean mice at endogenous leptin concentrations; (B) the
increase in leptin action during the acute response to pharmacological leptin
in lean mice, and (C) the much smaller increase in leptin action during the
acute response to pharmacologic leptin in DIO mice.
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Bjørbaek et al., 1998; Myers
et al., 2012), how could
Socs3 be elevated if LepRb
signaling is decreased?
What SOCS3 can do, though,
is limit the maximum
response to leptin; thus, while
LepRb signaling is increased
compared to lean animals
in the face of elevated endog-
enous leptin in DIO, LepRb
signaling in DIO is not
as high as it might be in
the absence of SOCS3,
and SOCS3 likely limits the
response to pharmacologic
leptin (Figure 1; Bjo¨rnholm
et al., 2007; Mori et al.,
2004). Consistent with this
notion, the constant infusion
of leptin into leptin-deficient
ob/ob animals revealed that
leptin treatment itself, rather
than obesity, blunts the
response to pharmacological
leptin (Knight et al., 2010).
How, then, do we define
and understand leptin resis-
tance? Since DIO animals
demonstrate an appropri-
ately elevated response to
high endogenous leptin, we
can’t say that they are obese
due to decreased leptin ac-
tion. Such animals are ex-
pected to respond poorly to
exogenous leptin, however,because leptin-induced SOCS3 limits
any additional LepRb signaling. Thus,
while there is no pathophysiologic
decrease in endogenous leptin action
that could promote obesity, leptin resis-
tance could be defined as the failure of
pharmacologic leptin to increase LepRb
signaling and physiologic responses
in hyperleptinemic obesity. Similarly,
while hypothalamic inflammation and
ER stress have also been suggested to
mediate leptin resistance in DIO (Ozcan792 Cell Metabolism 21, June 2, 2015 ª2015et al., 2009; Zhang et al., 2008), the
persistence of endogenous leptin action
in DIO animals also indicates that these
processes do not diminish LepRb
signaling or cellular leptin action below
baseline, although they could theoreti-
cally contribute to the impaired response
to pharmacologic leptin that defines
leptin resistance.
This does leave important questions,
though. Is there some blockage in the sys-
tem downstream of the cellular responseElsevier Inc.to leptin in DIO that prevents
the translation of elevated
cellular leptin action into a
catabolic drive capable of
deceasing adiposity to base-
line? Or is the level of obesity
achieved in DIO merely the
point at which the hedonic
drive to eat palatable food is
balanced by the increased
catabolic drive promoted by
hyperleptinemia?REFERENCES
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